As we are aware, Palmer has stated on numerous occasions that there is significant interest from potential partners in cetilistat. That is a fact that those potentially interested in the company as a whole will also be aware.
It is therefore my view that the obvious fact that AZM will be in partnership discussions with licensors re cetilistat may well also stimulate takeover offers, as once cetilistat has been partnered (other than Japan), AZM will be less of a desirable commodity for acquirers. There is thus a window of a few months where a takeover is both more likely than ever before (as cetilistat has now been near enough completely de-risked and renzapride/colal-pred are in PhIII) and more likely than it ever will be again (as post a global deal for cetilistat such a takeout could never be as clean for the purchaser).
In addition the likely positive Takeda PhI results anticipated soon will focus minds further as this will be a trial conducted entirely by a third party which if it confirms AZMs previous results (which obviously should be the case) will add further urgency to partners/purchasers activities otherwise they will be fearful of missing out.
Conclusion: The next few months should be an exciting time for AZM with either partner or takeover news being possible at any time.
Allianz Se stock quotes
Allianz Se stock charts
Follow this thread
